BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results